可切除非小细胞肺癌的诱导治疗：免疫肿瘤学时代拉开帷幕。 - Suppr

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds.

作者信息

Walker Paul R

机构信息

Division of Hematology/Oncology, Department of Medicine, Brody School of Medicine at East Carolina University, Greenville, NC, USA.

出版信息

J Thorac Dis. 2023 Jul 31;15(7):3533-3537. doi: 10.21037/jtd-23-699. Epub 2023 Jun 15.

DOI:10.21037/jtd-23-699

PMID:37559643

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10407505/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a1a/10407505/8983a92a4c39/jtd-15-07-3533-f1.jpg

相似文献

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds.可切除非小细胞肺癌的诱导治疗：免疫肿瘤学时代拉开帷幕。

J Thorac Dis. 2023 Jul 31;15(7):3533-3537. doi: 10.21037/jtd-23-699. Epub 2023 Jun 15.

Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.围手术期循环肿瘤 DNA 作为可切除的 I 期至 IIIA 期非小细胞肺癌的潜在预后标志物。

Cancer. 2022 Feb 15;128(4):708-718. doi: 10.1002/cncr.33985. Epub 2021 Oct 18.

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.循环肿瘤DNA可预测手术切除的非小细胞肺癌患者新辅助免疫治疗疗效及无复发生存期。

Transl Lung Cancer Res. 2022 Feb;11(2):263-276. doi: 10.21037/tlcr-22-106.

SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.非小细胞肺癌患者血浆循环肿瘤 DNA 中 SOX17 启动子甲基化。

Clin Chem Lab Med. 2016 Aug 1;54(8):1385-93. doi: 10.1515/cclm-2015-0776.

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.个体化循环肿瘤 DNA 检测监测免疫治疗疗效和预测局部晚期或转移性非小细胞肺癌的结局。

Cancer Med. 2023 Jul;12(13):14317-14326. doi: 10.1002/cam4.6108. Epub 2023 May 15.

Clinical value of peripheral blood circulating tumor DNA in predicting the efficacy of immunotherapy for non-small cell lung cancer.外周血循环肿瘤DNA在预测非小细胞肺癌免疫治疗疗效中的临床价值

J Thorac Dis. 2023 May 30;15(5):2659-2667. doi: 10.21037/jtd-23-379. Epub 2023 May 8.

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).新辅助纳武利尤单抗联合化疗治疗可手术 IIIA 期非小细胞肺癌的总生存和生物标志物分析（NADIM Ⅱ期试验）。

J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16.

Neoadjuvant immunotherapy for resectable non-small cell lung cancer.可切除非小细胞肺癌的新辅助免疫疗法

Am J Cancer Res. 2021 Jun 15;11(6):2521-2536. eCollection 2021.

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.免疫治疗时代前可切除 III 期非小细胞肺癌的长期预后：SAKK 16/96、SAKK 16/00、SAKK 16/01 和 SAKK 16/08 试验的汇总分析结果。

ESMO Open. 2022 Apr;7(2):100455. doi: 10.1016/j.esmoop.2022.100455. Epub 2022 Apr 7.

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.ctDNA 早期动力学联合 cfDNA 和血清 CEA 对晚期非小细胞肺癌 EGFR-TKI 治疗的预测价值。

Thorac Cancer. 2022 Nov;13(22):3162-3173. doi: 10.1111/1759-7714.14668. Epub 2022 Oct 4.

本文引用的文献

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.可切除非小细胞肺癌的新辅助化疗联合纳武利尤单抗加或不加伊匹单抗：Ⅱ期平台 NEOSTAR 试验。

Nat Med. 2023 Mar;29(3):593-604. doi: 10.1038/s41591-022-02189-0. Epub 2023 Mar 16.

The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review.可切除非小细胞肺癌诱导治疗新时代的开端：一项叙述性综述

J Thorac Dis. 2023 Feb 28;15(2):747-758. doi: 10.21037/jtd-22-957. Epub 2023 Feb 2.

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.新辅助-辅助或仅辅助派姆单抗治疗晚期黑色素瘤。

N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437.

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.新辅助纳武利尤单抗治疗可切除非小细胞肺癌的 5 年临床结果。

Clin Cancer Res. 2023 Feb 16;29(4):705-710. doi: 10.1158/1078-0432.CCR-22-2994.

Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.肺段或亚肺叶切除术治疗外周型ⅠA 期非小细胞肺癌。

N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.晚期非小细胞肺癌中循环肿瘤DNA引导治疗的总生存期

Nat Med. 2022 Nov;28(11):2353-2363. doi: 10.1038/s41591-022-02047-z. Epub 2022 Nov 10.

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.帕博利珠单抗对比安慰剂作为完全切除的 IB 期-IIIA 期非小细胞肺癌的辅助治疗（PEARLS/KEYNOTE-091）：一项随机、三盲、III 期试验的中期分析。

Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.

J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16.

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC.NSCLC 新辅助程序性死亡蛋白-1 抑制剂（信迪利单抗）治疗的 3 年随访结果。

J Thorac Oncol. 2022 Jul;17(7):909-920. doi: 10.1016/j.jtho.2022.04.012. Epub 2022 May 10.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。

N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献